Rinri was established in 2018 by Marcelo Rivolta, a Professor of Sensory Stem Cell Biology, who has dedicated his research to discovering new regenerative therapeutics for hearing loss. With a hope to tackle the unmet medical need faced by millions of people across the world and make a significant impact on both the lives of patients and healthcare systems globally.
Drawing from this research, Rinri Therapeutics is now developing the world’s first regenerative cell therapies for hearing loss. Rinri’s therapy will have the ability to replace the dead or damaged specialised sensory cells of the inner ear that cause sensorineural hearing loss, the most common form of the condition. Rinri’s therapies are the first to have demonstrated that cell therapy has the potential to reverse hearing loss.
Rinri, which means ‘ear’ in Quechua – an indigenous language of South America – is now accelerating the preclinical development of its technology through to hopefully being the first to deliver first-in-human (FIH) clinical trials in the near future.